ESMO摘要速遞：科濟藥業CT041 CAR-T治療消化道腫瘤最新進展

全球首創的CLDN18.2 CAR-T細胞藥物被美國FDA授予“孤兒藥”稱號

CARsgen Therapeutics Receives IND Clearance from the NMPA for CT041 CLDN18.2-CAR-T Cells

CARsgen Announces the Publication of a Novel CAR-T Technology that Improves the Efficacy of CAR-T cells Against Solid Tumors without Requiring Preconditioned Lymphodepletion

CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells (CT053) for the Treatment of Multiple Myeloma

科濟生物任命範勇博士擔任全球註冊事務高級副總裁